Format

Send to

Choose Destination
Eur J Cancer. 2016 Jul;62:132-7. doi: 10.1016/j.ejca.2016.03.081. Epub 2016 May 14.

RECIST 1.1-Update and clarification: From the RECIST committee.

Author information

1
Department of Radiology, Columbia University Medical Center, New York, NY, USA; New York Presbyterian Hospital, New York, NY, USA. Electronic address: LSchwartz@columbia.edu.
2
EORTC HQ, Brussels, Belgium.
3
Department of Internal Medicine, University Medical Center Groningen, Groningen, The Netherlands.
4
Clinical Trials Imaging Consulting, NJ, USA.
5
Department of Medical Imaging, East Surrey Hospital, Redhill, Surrey, UK.
6
Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
7
Clinical Trials Branch, Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
8
Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
9
Canadian Cancer Trials Group, Queen's University, Kingston, Canada.
10
Exploratory Clinical & Translational Research, Bristol-Myers Squibb, Princeton, NJ, USA.
11
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
12
Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands.
13
National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
14
Laboratoires Servier, Paris, France.
15
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical and Graduate Colleges, New York, NY, USA; Ludwig Institute for Cancer Research, New York, NY, USA.

Abstract

The Response Evaluation Criteria in Solid Tumours (RECIST) were developed and published in 2000, based on the original World Health Organisation guidelines first published in 1981. In 2009, revisions were made (RECIST 1.1) incorporating major changes, including a reduction in the number of lesions to be assessed, a new measurement method to classify lymph nodes as pathologic or normal, the clarification of the requirement to confirm a complete response or partial response and new methodologies for more appropriate measurement of disease progression. The purpose of this paper was to summarise the questions posed and the clarifications provided as an update to the 2009 publication.

KEYWORDS:

Clarifications; RECIST; Tumour response

PMID:
27189322
PMCID:
PMC5737828
DOI:
10.1016/j.ejca.2016.03.081
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center